Leukemia & Lymphoma Society

Stemline Therapeutics, Leukemia & Lymphoma Society collaborate

Wednesday, October 30, 2013

Stemline Therapeutics, a clinical-stage biopharmaceutical company developing novel oncology therapeutics, and The Leukemia & Lymphoma Society (LLS) are collaborating to accelerate the development of SL-401 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematological disorder with both leukemic and lymphomatous characteristics.

[Read More]

LLS, Valor Biotherapeutics partner to advance novel therapy

Thursday, May 30, 2013

The Leukemia & Lymphoma Society (LLS), a global voluntary health agency,  is committing approximately $6 million to Valor Biotherapeutics, a joint venture of biotechnology companies ImmunGene and Caliber, to co-fund the completion of preclinical development, manufacturing and a phase I clinical trial for a novel fusion protein that may change the poor outcomes faced by many patients with indolent lymphomas who do not respond to standard therapy with rituximab.

[Read More]